Key result
Semaglutide kidney, major cardiovascular events, and mortality benefits do not differ across racial or ethnic groups.
Why the study?
Potential variation in semaglutide treatment response across racial and ethnic groups of people with chronic kidney disease and type 2 diabetes had not been assessed.
Does once-weekly subcutaneous semaglutide 1.0 mg compared to placebo exhibit differential efficacy on kidney, cardiovascular, and mortality outcomes across racial and ethnic subgroups of patients with chronic kidney disease and type 2 diabetes?
RCT (n=3,533)
Randomized
Yes
Does once-weekly subcutaneous semaglutide 1.0 mg compared to placebo exhibit differential efficacy on kidney, cardiovascular, and mortality outcomes across racial and ethnic subgroups of patients with chronic kidney disease and type 2 diabetes?
Semaglutide 1.0 mg provides consistent kidney, cardiovascular, and mortality benefits across racial and ethnic groups in patients with type 2 diabetes and chronic kidney disease.
Answers are grounded in this paper and cite their sources.
Supports semaglutide use irrespective of race/ethnicity in T2D-CKD; confirms generalizability of benefits across RCT subgroups.
Background: Potential variation in semaglutide treatment response across racial and ethnic groups of people with chronic kidney disease and type 2 diabetes has not been assessed. In a post hoc analysis of the international FLOW randomized controlled clinical trial, we assessed the efficacy of once-weekly subcutaneous semaglutide 1.0 mg vs placebo on kidney and cardiovascular outcomes in racial and ethnic subgroups. Methods: Using FLOW trial data, we compared semaglutide 1.0 mg vs placebo (in addition to the standard of care) on the primary kidney outcome (onset of kidney failure, ≥50% reduction in estimate glomerular filtration rate [eGFR] from baseline sustained for ≥28 days, or death from kidney-related or cardiovascular causes) and three confirmatory secondary outcomes (annual change [total slope] in eGFR, major adverse cardiovascular events [MACE], and all-cause death) between Black/African American and non-Black/African American participants and between Hispanic/Latino and non-Hispanic/Latino participants. Cox proportional hazards models were used to compare semaglutide 1.0 mg vs placebo groups on the occurrence of the primary kidney outcome, MACE, and all-cause death. Random-effects linear regression models were used to compare groups on the change in eGFR. Models included interaction terms for treatment by race or ethnicity. Results: Of 3,533 total participants in the FLOW trial, 3,454 had race data available (Black/African American, n=160; non-Black/African American, n=3,294), and 3,388 had ethnicity data available (Hispanic/Latino, n=556; non-Hispanic Latino, n=2,832). Over a median 3.4 years of follow-up, the effect of semaglutide on the primary kidney outcome, MACE, all-cause death, and annual change in eGFR did not statistically significantly differ between Black/African American and non-Black/African American participants or between Hispanic/Latino and non-Hispanic/Latino participants (all interaction P-values >0.05). Conclusion: In this post hoc exploratory analysis of the FLOW trial, there was no statistical evidence that the efficacy of semaglutide treatment on kidney and cardiovascular outcomes differed by race or ethnicity.
No takes yet. Share an insight, caveat, or question.
Campos et al. (2026) conducted an RCT in Chronic kidney disease and type 2 diabetes (n=3,533). Semaglutide vs. Placebo (in addition to standard of care) was evaluated on Onset of kidney failure, >=50% reduction in eGFR from baseline sustained for >=28 days, or death from kidney-related or cardiovascular causes (p=>0.05 for interaction). Semaglutide once-weekly efficacy on primary kidney outcomes, major cardiovascular events, and mortality did not differ across racial or ethnic groups.
Synapse has enriched 10 related papers. Consider them for comparative context: